Advanced search
Publication Cover
Leukemia & Lymphoma Volume 65, 2024 - Issue 6
Submit an article Journal homepage
145
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

A second round of anti-CD19 CAR T-cell therapy in diffuse large B-cell lymphoma: when persistence pays off

Marie Leroya CHU Lille, Institut de Pharmacie, Lille, FranceView further author information
,
Laure Deramoudta CHU Lille, Institut de Pharmacie, Lille, France;b Univ Lille, ULR 7365-GRITA-Groupe de Recherche sur les Formes Injectables et les Technologies Associées, Lille, FranceView further author information
,
Marine Pinturauda CHU Lille, Institut de Pharmacie, Lille, France;b Univ Lille, ULR 7365-GRITA-Groupe de Recherche sur les Formes Injectables et les Technologies Associées, Lille, FranceView further author information
,
Julie Demaretc CHU Lille, Institut d‘Immunologie, Lille, France;d CHU de Lille, Université de Lille, INSERM Infinite U1285, Lille, FranceView further author information
,
Enagnon Kazali Alidjinoue Virology Laboratory, ULR 3610, CHU Lille, University of Lille, Lille, FranceView further author information
,
Morgane Nudelf Hematology Department, CHU Lille, Lille, FranceView further author information
,
Doriane Cavalierif Hematology Department, CHU Lille, Lille, FranceView further author information
,
Wadih Abou Chahlag Department of Pediatric Hematology, Jeanne de Flandre Hospital, Lille University Hospital, Lille, FranceView further author information
,
Pascal Odoua CHU Lille, Institut de Pharmacie, Lille, France;b Univ Lille, ULR 7365-GRITA-Groupe de Recherche sur les Formes Injectables et les Technologies Associées, Lille, FranceView further author information
,
Franck Morschhauserb Univ Lille, ULR 7365-GRITA-Groupe de Recherche sur les Formes Injectables et les Technologies Associées, Lille, France;f Hematology Department, CHU Lille, Lille, FranceView further author information
,
Ibrahim Yakoub-Aghad CHU de Lille, Université de Lille, INSERM Infinite U1285, Lille, France;f Hematology Department, CHU Lille, Lille, FranceView further author information
,
Nicolas Simona CHU Lille, Institut de Pharmacie, Lille, France;b Univ Lille, ULR 7365-GRITA-Groupe de Recherche sur les Formes Injectables et les Technologies Associées, Lille, FranceView further author information
&
David Beauvaisf Hematology Department, CHU Lille, Lille, France;h Univ Lille, Inserm U1192 - PRISM, Lille, FranceCorrespondence[email protected]
View further author information
 show all
Pages 868-871 | Received 26 Nov 2023, Accepted 24 Feb 2024, Published online: 05 Mar 2024

References

  • Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20(1):31–42. doi:10.1016/S1470-2045(18)30864-7
  • Schuster SJ, Tam CS, Borchmann P, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22(10):1403–1415. doi:10.1016/S1470-2045(21)00375-2
  • Neelapu SS, Jacobson CA, Ghobadi A, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023;141(19):2307–2315. doi:10.1182/blood.2022018893
  • Di Blasi R, Le Gouill S, Bachy E, et al. Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis. Blood. 2022;140(24):2584–2593. doi:10.1182/blood.2022016945
  • Gauthier J, Bezerra ED, Hirayama AV, et al. Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies. Blood. 2021;137(3):323–335. doi:10.1182/blood.2020006770
  • Chow VA, Gopal AK, Gauthier J, et al. Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy. Blood Adv. 13 oct 2020;4(19):4869–4872. doi:10.1182/bloodadvances.2020002292
  • Holland EM, Molina JC, Dede K, et al. Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation. J Immunother Cancer. 2022;10(5):e004483. doi:10.1136/jitc-2021-004483
  • Schultz LM, Eaton A, Baggott C, et al. Outcomes after nonresponse and relapse Post-Tisagenlecleucel in children, adolescents, and young adults with B-cell acute lymphoblastic leukemia. J Clin Oncol. 2023;41(2):354–363. doi:10.1200/JCO.22.01076
  • Bezerra ED, Gauthier J, Hirayama AV, et al. Factors associated with response, CAR-T cell in vivo expansion, and progression-Free survival after repeat infusions of CD19 CAR-T cells. Blood. 2019;134(Suppl 1):201–201. doi:10.1182/blood-2019-123807
  • Galletta TJ, Rubinstein JD, Krupski C, et al. Durable remissions achieved with reinfusion of CD19-directed CAR-T despite failure to induce or maintain B-cell aplasia and single-center experience with reinfusion of tisagenlecleucel. Pediatr Blood Cancer. 2023;70(5):e30271. doi:10.1002/pbc.30271
  • Pulsipher MA, Han X, Maude SL, et al. Next-Generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia. Blood Cancer Discov. 2022;3(1):66–81. doi:10.1158/2643-3230.BCD-21-0095
  • Kwon M, Iacoboni G, Reguera JL, et al. Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma. Haematologica. 2023;108(1):110–121. doi:10.3324/haematol.2022.280805
  • Mehta PH, Fiorenza S, Koldej RM, et al. T cell fitness and autologous CAR T cell therapy in haematologic malignancy. Front Immunol. 2021;12:780442. doi:10.3389/fimmu.2021.780442
  • Fraietta JA, Lacey SF, Orlando EJ, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24(5):563–571. doi:10.1038/s41591-018-0010-1
  • Korell F, Laier S, Sauer S, et al. Current challenges in providing good leukapheresis products for manufacturing of CAR-T cells for patients with relapsed/refractory NHL or ALL. Cells. 2020;9(5):1225. doi:10.3390/cells9051225
  • Myers RM, Li Y, Barz Leahy A, et al. Humanized CD19-Targeted chimeric antigen receptor (CAR) T cells in CAR-Naive and CAR-Exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia. J Clin Oncol. 2021;39(27):3044–3055. doi:10.1200/JCO.20.03458
  • Michelozzi IM, Gomez-Castaneda E, Pohle RVC, et al. Activation priming and cytokine polyfunctionality modulate the enhanced functionality of low-affinity CD19 CAR T cells. Blood Adv. 2023;7(9):1725–1738. doi:10.1182/bloodadvances.2022008490
  • Zhao Z, Condomines M, van der Stegen SJC, et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell. 2015;28(4):415–428. doi:10.1016/j.ccell.2015.09.004
  • Bachy E, Le Gouill S, Di Blasi R, et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med. 2022;28(10):2145–2154. doi:10.1038/s41591-022-01969-y

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.